Association between Nafamostat Mesylate and In-Hospital Mortality in Patients with Coronavirus Disease 2019: A Multicenter Observational Study
Nafamostat mesylate may be effective against coronavirus disease 2019 (COVID-19). However, it is not known whether its use is associated with reduced in-hospital mortality in clinical practice. We conducted a retrospective observational study to evaluate the effect of nafamostat mesylate in patients...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-12-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/11/1/116 |
| _version_ | 1797498693290557440 |
|---|---|
| author | Ryota Inokuchi Toshiki Kuno Jun Komiyama Kazuaki Uda Yoshihisa Miyamoto Yuta Taniguchi Toshikazu Abe Miho Ishimaru Motohiko Adomi Nanako Tamiya Masao Iwagami |
| author_facet | Ryota Inokuchi Toshiki Kuno Jun Komiyama Kazuaki Uda Yoshihisa Miyamoto Yuta Taniguchi Toshikazu Abe Miho Ishimaru Motohiko Adomi Nanako Tamiya Masao Iwagami |
| author_sort | Ryota Inokuchi |
| collection | DOAJ |
| description | Nafamostat mesylate may be effective against coronavirus disease 2019 (COVID-19). However, it is not known whether its use is associated with reduced in-hospital mortality in clinical practice. We conducted a retrospective observational study to evaluate the effect of nafamostat mesylate in patients with COVID-19 using the Medical Data Vision Co. Ltd. hospital-based database in Japan. We compared patients with COVID-19 who were (<i>n</i> = 121) and were not (<i>n</i> = 15,738) administered nafamostat mesylate within 2 days of admission between January and December 2020. We conducted a 1:4 propensity score matching with multiple imputations for smoking status and body mass index and combined the 20 imputed propensity score-matched datasets to obtain the adjusted odds ratio for in-hospital mortality. Crude in-hospital mortality was 13.2% (16/121) and 5.0% (790/15,738), respectively. In the propensity score-matched analysis with multiple imputations, the adjusted odds ratio (use vs. no use of nafamostat mesylate) for in-hospital mortality was 1.27 (95% confidence interval: 0.61–2.64; <i>p</i> = 0.52). Sensitivity analyses showed similar results. The results of this retrospective observational study did not support an association between nafamostat mesylate and improved in-hospital outcomes in patients with COVID-19, although further studies with larger sample sizes are warranted to assess the generalizability of our findings. |
| first_indexed | 2024-03-10T03:36:59Z |
| format | Article |
| id | doaj.art-bcc6f16a7ede4807bb5ec76c3c4bbc49 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-10T03:36:59Z |
| publishDate | 2021-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-bcc6f16a7ede4807bb5ec76c3c4bbc492023-11-23T11:43:52ZengMDPI AGJournal of Clinical Medicine2077-03832021-12-0111111610.3390/jcm11010116Association between Nafamostat Mesylate and In-Hospital Mortality in Patients with Coronavirus Disease 2019: A Multicenter Observational StudyRyota Inokuchi0Toshiki Kuno1Jun Komiyama2Kazuaki Uda3Yoshihisa Miyamoto4Yuta Taniguchi5Toshikazu Abe6Miho Ishimaru7Motohiko Adomi8Nanako Tamiya9Masao Iwagami10Department of Health Services Research, Faculty of Medicine, University of Tsukuba, Tsukuba 305-8575, JapanMontefiore Medical Center, Division of Cardiology, Albert Einstein College of Medicine, New York, NY 10461, USADepartment of Health Services Research, Faculty of Medicine, University of Tsukuba, Tsukuba 305-8575, JapanHealth Services Research and Development Center, University of Tsukuba, Tsukuba 305-8575, JapanNational Cancer Center, Institute for Cancer Control, Tokyo 104-0045, JapanGraduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba 305-8575, JapanDepartment of Health Services Research, Faculty of Medicine, University of Tsukuba, Tsukuba 305-8575, JapanDepartment of Health Services Research, Faculty of Medicine, University of Tsukuba, Tsukuba 305-8575, JapanDepartment of Health Services Research, Faculty of Medicine, University of Tsukuba, Tsukuba 305-8575, JapanDepartment of Health Services Research, Faculty of Medicine, University of Tsukuba, Tsukuba 305-8575, JapanDepartment of Health Services Research, Faculty of Medicine, University of Tsukuba, Tsukuba 305-8575, JapanNafamostat mesylate may be effective against coronavirus disease 2019 (COVID-19). However, it is not known whether its use is associated with reduced in-hospital mortality in clinical practice. We conducted a retrospective observational study to evaluate the effect of nafamostat mesylate in patients with COVID-19 using the Medical Data Vision Co. Ltd. hospital-based database in Japan. We compared patients with COVID-19 who were (<i>n</i> = 121) and were not (<i>n</i> = 15,738) administered nafamostat mesylate within 2 days of admission between January and December 2020. We conducted a 1:4 propensity score matching with multiple imputations for smoking status and body mass index and combined the 20 imputed propensity score-matched datasets to obtain the adjusted odds ratio for in-hospital mortality. Crude in-hospital mortality was 13.2% (16/121) and 5.0% (790/15,738), respectively. In the propensity score-matched analysis with multiple imputations, the adjusted odds ratio (use vs. no use of nafamostat mesylate) for in-hospital mortality was 1.27 (95% confidence interval: 0.61–2.64; <i>p</i> = 0.52). Sensitivity analyses showed similar results. The results of this retrospective observational study did not support an association between nafamostat mesylate and improved in-hospital outcomes in patients with COVID-19, although further studies with larger sample sizes are warranted to assess the generalizability of our findings.https://www.mdpi.com/2077-0383/11/1/116coronavirus disease 2019in-hospital mortalitynafamostat mesylate |
| spellingShingle | Ryota Inokuchi Toshiki Kuno Jun Komiyama Kazuaki Uda Yoshihisa Miyamoto Yuta Taniguchi Toshikazu Abe Miho Ishimaru Motohiko Adomi Nanako Tamiya Masao Iwagami Association between Nafamostat Mesylate and In-Hospital Mortality in Patients with Coronavirus Disease 2019: A Multicenter Observational Study Journal of Clinical Medicine coronavirus disease 2019 in-hospital mortality nafamostat mesylate |
| title | Association between Nafamostat Mesylate and In-Hospital Mortality in Patients with Coronavirus Disease 2019: A Multicenter Observational Study |
| title_full | Association between Nafamostat Mesylate and In-Hospital Mortality in Patients with Coronavirus Disease 2019: A Multicenter Observational Study |
| title_fullStr | Association between Nafamostat Mesylate and In-Hospital Mortality in Patients with Coronavirus Disease 2019: A Multicenter Observational Study |
| title_full_unstemmed | Association between Nafamostat Mesylate and In-Hospital Mortality in Patients with Coronavirus Disease 2019: A Multicenter Observational Study |
| title_short | Association between Nafamostat Mesylate and In-Hospital Mortality in Patients with Coronavirus Disease 2019: A Multicenter Observational Study |
| title_sort | association between nafamostat mesylate and in hospital mortality in patients with coronavirus disease 2019 a multicenter observational study |
| topic | coronavirus disease 2019 in-hospital mortality nafamostat mesylate |
| url | https://www.mdpi.com/2077-0383/11/1/116 |
| work_keys_str_mv | AT ryotainokuchi associationbetweennafamostatmesylateandinhospitalmortalityinpatientswithcoronavirusdisease2019amulticenterobservationalstudy AT toshikikuno associationbetweennafamostatmesylateandinhospitalmortalityinpatientswithcoronavirusdisease2019amulticenterobservationalstudy AT junkomiyama associationbetweennafamostatmesylateandinhospitalmortalityinpatientswithcoronavirusdisease2019amulticenterobservationalstudy AT kazuakiuda associationbetweennafamostatmesylateandinhospitalmortalityinpatientswithcoronavirusdisease2019amulticenterobservationalstudy AT yoshihisamiyamoto associationbetweennafamostatmesylateandinhospitalmortalityinpatientswithcoronavirusdisease2019amulticenterobservationalstudy AT yutataniguchi associationbetweennafamostatmesylateandinhospitalmortalityinpatientswithcoronavirusdisease2019amulticenterobservationalstudy AT toshikazuabe associationbetweennafamostatmesylateandinhospitalmortalityinpatientswithcoronavirusdisease2019amulticenterobservationalstudy AT mihoishimaru associationbetweennafamostatmesylateandinhospitalmortalityinpatientswithcoronavirusdisease2019amulticenterobservationalstudy AT motohikoadomi associationbetweennafamostatmesylateandinhospitalmortalityinpatientswithcoronavirusdisease2019amulticenterobservationalstudy AT nanakotamiya associationbetweennafamostatmesylateandinhospitalmortalityinpatientswithcoronavirusdisease2019amulticenterobservationalstudy AT masaoiwagami associationbetweennafamostatmesylateandinhospitalmortalityinpatientswithcoronavirusdisease2019amulticenterobservationalstudy |